

Referenties test 1

1. Actuele cijfers hart- en vaatziekten | Hartstichting. Geraadpleegd op 3 juli 2024.
2. Koop Y, Wimmers RH, Bots ML, et al. Basiscijfers hartfalen 2022. Hartstichting, <https://www.hartenvaatcijfers.nl/jaarcijfers/jaarcijfers-hartfalen-40b27>. Geraadpleegd op: 3 juli 2024.
3. McDonagh, T. A., Metra, M., Adamo, M. et al., ESC Scientific Document Group (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European heart journal, 42(36), 3599–3726. <https://doi.org/10.1093/eurheartj/ehab368>.
4. McDonagh, T. A., Metra, M., Adamo, M. et al., ESC Scientific Document Group (2023). 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European heart journal, 44(37), 3627–3639. <https://doi.org/10.1093/eurheartj/ehad195>
5. Mebazaa, A., Davison, B., Chioncel, O. et al., (2022). Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet (London, England), 400(10367), 1938–1952. [https://doi.org/10.1016/S0140-6736\(22\)02076-1](https://doi.org/10.1016/S0140-6736(22)02076-1)
6. Parén, P., Schaufelberger, M., Björck, L., Lappas, G., Fu, M., & Rosengren, A. (2014). Trends in prevalence from 1990 to 2007 of patients hospitalized with heart failure in Sweden. European journal of heart failure, 16(7), 737–742. <https://doi.org/10.1002/ejhf.109>
7. Mamas, M. A., Sperrin, M., Watson, M. C., et al. (2017). Do patients have worse outcomes in heart failure than in cancer? European journal of heart failure, 19(9), 1095–1104. <https://doi.org/10.1002/ejhf.822>

Source URL: <https://www.pro.novartis.com/nl-nl/node/431>